NOVOEIGHT 250 IU

Maa: Israel

Kieli: englanti

Lähde: Ministry of Health

Osta se nyt

Lataa Pakkausseloste (PIL)
02-04-2019
Lataa Valmisteyhteenveto (SPC)
17-02-2019

Aktiivinen ainesosa:

TUROCTOCOG ALFA

Saatavilla:

NOVO NORDISK LTD, ISRAEL

ATC-koodi:

B02BD02

Lääkemuoto:

POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Koostumus:

TUROCTOCOG ALFA 250 IU / 4 ML

Antoreitti:

I.V

Prescription tyyppi:

Required

Valmistaja:

NOVO NORDISK A/S, DENMARK

Terapeuttinen alue:

COAGULATION FACTOR VIII

Käyttöaiheet:

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).NovoEight can be used for all age groups.

Valtuutus päivämäärä:

2015-09-21

Valmisteyhteenveto

                                1
The content of this leaflet was approved by the Ministry of Health in
September 2015 and updated
according to the guidelines of the Ministry of Health in January 2019
1.
NAME OF THE MEDICINAL PRODUCT
NovoEight 250 IU powder and solvent for solution for injection
NovoEight 500 IU powder and solvent for solution for injection
NovoEight 1000 IU powder and solvent for solution for injection
NovoEight 1500 IU powder and solvent for solution for injection
NovoEight 2000 IU powder and solvent for solution for injection
NovoEight 3000 IU powder and solvent for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
NovoEight 250 IU powder and solvent for solution for injection.
Each powder vial contains nominally 250 IU human coagulation factor
VIII (rDNA), turoctocog alfa.
After reconstitution NovoEight contains approximately 62.5 IU/ml of
human coagulation factor VIII
(rDNA), turoctocog alfa.
NovoEight 500 IU powder and solvent for solution for injection.
Each powder vial contains nominally 500 IU human coagulation factor
VIII (rDNA), turoctocog alfa.
After reconstitution NovoEight contains approximately 125 IU/ml of
human coagulation factor VIII
(rDNA), turoctocog alfa.
NovoEight 1000 IU powder and solvent for solution for injection.
Each powder vial contains nominally 1000 IU human coagulation factor
VIII (rDNA), turoctocog alfa.
After reconstitution NovoEight contains approximately 250 IU/ml of
human coagulation factor VIII
(rDNA), turoctocog alfa.
NovoEight 1500 IU powder and solvent for solution for injection.
Each powder vial contains nominally 1500 IU human coagulation factor
VIII (rDNA), turoctocog alfa.
After reconstitution NovoEight contains approximately 375 IU/ml of
human coagulation factor VIII
(rDNA), turoctocog alfa.
NovoEight 2000 IU powder and solvent for solution for injection.
Each powder vial contains nominally 2000 IU human coagulation factor
VIII (rDNA), turoctocog alfa.
After reconstitution NovoEight contains approximately 500 IU/ml of
human coagulation factor VIII
(rDNA), turoctocog
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste arabia 15-07-2019
Pakkausseloste Pakkausseloste heprea 15-07-2019

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia